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Abstract: Rhodium-catalyzed C@H insertions and cyclo-
propanations of donor/acceptor carbenes have been used
for the synthesis of positional analogues of methylpheni-
date. The site selectivity is controlled by the catalyst and
the amine protecting group. C@H functionalization of N-
Boc-piperidine using Rh2(R-TCPTAD)4, or N-brosyl-piperi-
dine using Rh2(R-TPPTTL)4 generated 2-substitited ana-
logues. In contrast, when N-a-oxoarylacetyl-piperidines
were used in combination with Rh2(S-2-Cl-5-BrTPCP)4, the
C@H functionalization produced 4-susbstiuted analogues.
Finally, the 3-substituted analogues were prepared indi-
rectly by cyclopropanation of N-Boc-tetrahydropyridine
followed by reductive regio- and stereoselective ring-
opening of the cyclopropanes.
The piperidine ring with substituents at different positions is a
prominent structural element in numerous pharmaceuticals,[1]
including Ritalin (methylphenidate), a therapeutic agent for at-
tention deficit hyperactivity disorder.[2] Traditional synthetic
routes to these heterocycles typically involve ring construction
or require functionalized piperidines,[2, 3] with the latter being
challenging owing to the lack of readily available enantiopure
piperidine precursors. An alternative strategy would be the
direct, site selective C@H functionalization, ideally at any posi-
tion of the piperidine moiety at will. Many examples have
been disclosed on the use of C@H functionalization as a key
disconnection strategy for the synthesis of natural products
and pharmaceutical targets.[4] The majority of these applica-
tions rely on using either directing groups[5] in the substrate or
on the inherent reactivity[6] of the substrate to control-site se-
lectivity. Considerable interest has also been shown in develop-
ing catalyst-controlled[6c, 7] or enzyme-controlled[8] C@H func-
tionalization reactions. The C@H functionalization at the C2 po-
sition on piperidine derivatives has been achieved using sever-
al different approaches.[9] However, selective functionalization
at the remote positions of the piperidine moiety, that is, C3
and C4, is limited.[10, 11]
We have been exploring the rhodium-catalyzed reactions of
donor/acceptor carbenes for catalyst-controlled C@H
functionalization.[6c,7f] Recently, we have designed catalysts that
are capable of selective functionalization of inactivated pri-
mary, secondary, and tertiary C@H bonds,[12] inactivated C@H
bonds over electronically activated C@H bonds,[13] and desym-
metrization of alkylcyclohexanes.[14] In this project, we describe
the application of these catalysts to generate methylphenidate
analogues with substituents at either C2, C3, or C4 of the pi-
peridine rings starting from appropriate piperidine derivatives
(Figure 1). The C@H functionalization at C2 is electronically pre-
ferred, because the build-up of positive charge at carbon
during the C@H functionalization would be stabilized by the ni-
trogen group.[15, 16] The C@H bond at C3 would be deactivated
through the inductive effect of nitrogen. The electronic deacti-
vation would be less for C4, which should be sterically the
Figure 1. Synthetic strategies towards C@H functionalization of piperidines
at C2, C3 and C4. C2@H: electronically activated but sterically hindered; C3@
H: electronically deactivated through inductive effect of NPg, indirect ap-
proach through regio- and stereoselective cyclopropane ring opening; C4@
H: accessible if the electronic preference for C2 can be overridden by steric
shielding of catalyst and NPg.
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most accessible position. Thus, a direct functionalization of the
C@H bond at C4 should be feasible by sterically shielding at C2
position, whereas we envisioned that C@H activation at C3
might become possible by an indirect approach via regioselec-
tive ring-opening of an appropriate cyclopropanated tetrahy-
dropyridine.
The first stage of this project was to optimize the C2 func-
tionalization of piperidines. The basic transformation is one of
the early classic C@H functionalization reactions of donor/ac-
ceptor carbenes, described independently by Davies[15] and
Winkler.[16] In the original studies, the control of both the dia-
stereoselectivity and enantioselectivity of the C@H functionali-
zation was relatively moderate. Therefore, we decided to re-ex-
amine this transformation using the specialized chiral dirhodi-
um catalysts that have been recently developed. The key opti-
mization studies are summarized in Table 1 and Scheme 1 (see
the Supporting Information for more extensive details). The
original Rh2(S-DOSP)4-catalyzed reaction of methyl aryldiazo-
acetate 2 a reacting with N-Boc-piperidine 1 a gives a 1:1 mix-
ture of diastereomers.[15] Several of the newer chiral dirhodium
tetracarboxylate catalysts (Table 1<xtabr1) were tested under
the same reaction conditions. Most of the catalysts furnished
the C2-functionalized product 4 a with 1:1 to 2:1 d.r. (entries 2–
4) and low to moderate enantioselectivity (27–66 % ee), where-
as the C4-symmetric catalyst, Rh2(S-2-Cl-5-BrTPCP)4, enhanced
the stereoselectivity to 5.3:1 d.r. and 83 % ee for the major dia-
stereomer 4 a (entry 5). Another major advance in site-selective
C@H functionalization has been the use of aryldiazoacetates
containing trichloroethyl esters instead of methyl esters as
donor/acceptor carbene precursors.[17] Hence, we evaluated
the influence of the ester switch on the stereoselectivity of the
C2 functionalization. The level of diastereoselectivity in the re-
action of 1 a using trichloroethyl derivative 3 a, catalyzed by
Rh2(S-2-Cl-5-BrTPCP)4, dropped considerably versus the methyl
ester (entry 6). Fortunately, the Rh2(R-TCPTAD)4-catalyzed trans-
formation to form 5 a lead to a considerable improvement in
the stereoselectivity (11:1 d.r. , 93 % ee) in 83 % yield (entry 7).
The diastereoselectivity was greatly improved (27:1 d.r.) when
Rh2(R-TPPTTL)4 was used as catalyst, but with lower enantiose-
lectivity (69 % ee, entry 8). Higher enantioselectivity (77 % ee)
with Rh2(R-TPPTTL)4 was obtained when an arylsulfonyl piperi-
dine derivative 1 b was used (6 a, entry 9). Further optimization
of the temperature showed improvement in yield with only a
small decrease in stereoselectivity at higher temperature
(39 8C: 87 % yield, 22:1 d.r. , 76 % ee, entry 10), whereas the re-
action at 0 8C caused declines in both yield and stereoselectiv-
ity (entry 11).
The scope of the C2 functionalization of piperidine was ex-
amined using the two most promising conditions, N-Boc-piper-
idine functionalization catalyzed by Rh2(R-TCPTAD)4 and N-Bs-
Table 1. Optimization studies for C2 functionalization.[a]




1[e,f] 1 a (Boc) 2 a (CH3) S-DOSP 69 1.5:1 @69
2[f] 1 a (Boc) 2 a (CH3) R-TCPTAD 69 1.4:1 66
3[f] 1 a (Boc) 2 a (CH3) R-p-BrTPCP 41 1.2:1 27
4[f] 1 a (Boc) 2 a (CH3) R-TPPTTL 69 1.5:1 54
5[f] 1 a (Boc) 2 a (CH3) S-2-Cl-5-BrTPCP 83 5.3:1 83
6[f] 1 a (Boc) 3 a (CH2CCl3) S-2-Cl-5-BrTPCP 73 3.6:1 65
7[f] 1 a (Boc) 3 a (CH2CCl3) R-TCPTAD 83 11:1 93
8[f] 1 a (Boc) 3 a (CH2CCl3) R-TPPTTL 80 27:1 69
9 1 b (Bs) 3 a (CH2CCl3) R-TPPTTL 76 >30:1 77
10[g] 1 b (Bs) 3 a (CH2CCl3) R-TPPTTL 87 22:1 76
11[h] 1 b (Bs) 3 a (CH2CCl3) R-TPPTTL 42 26:1 72
[a] Reaction conditions: a solution of 2 a–3 a (0.5 mmol) in 4 mL pentane/CH2Cl2 was added over 2 h to the solution of Rh2L4 (0.5 mol %) and 1 a,b
(0.75 mmol) in 2 mL pentane/CH2Cl2. [b] Yield of isolated material. [c] Determined from crude
1H NMR. [d] Determined by chiral HPLC analysis of isolated
product. [e] Reaction in pentane instead of CH2Cl2. [f] Analysis of yield, d.r. and ee were on free amine product after Boc-deprotection via trifluoroacetic
acid. [g] Reaction at refluxing CH2Cl2 (39 8C). [h] Reaction at 0 8C. Boc = tert-butyloxycarbonyl, Bs = p-bromo-phenylsulfonyl. The absolute stereochemistry
was deduced by comparison of products to those of the earlier study[15a] and confirmed by crystal structure of 6 a.
Scheme 1. Catalyst structures.




piperidine functionalization catalyzed by Rh2(R-TPPTTL)4
(Scheme 2). The Rh2(R-TCPTAD)4-catalyzed reactions gave mod-
erate yield but variable stereoselectivity, reaching low levels
with electron deficient aryldiazoacetates. In contrast, the Rh2(R-
TPPTTL)4-catalyzed reactions were highly diastereoselective for
all the substrates (29->30:1 d.r.) and maintained relatively
constant levels of enantioselectivity (52–73 % ee).
Having established the C2 functionalization of piperidine,
we then explored how to introduce the arylacetate group at
the C3 position. The direct C@H functionalization of piperidines
was not considered to be a viable option, because the C3 posi-
tion would be deactivated towards carbene C@H insertions
caused by the inductively electron-withdrawing effect of the
nitrogen. Therefore, we explored an indirect approach through
asymmetric cyclopropanation of a tetrahydropyridine followed
by a reductive ring opening of the cyclopropane intermediate.
A catalyst screen was conducted on the cyclopropanation of
the N-Boc-tetrahydropyridine 7 to generate 8 and the key re-
sults are shown in Table 2 (see the Supporting Information for
more extensive details). It is well established that Rh2(R-DOSP)4
performs best when the methyl ester of aryldiazoacetates and
hydrocarbon solvents are used.[6c] The classic catalyst, Rh2(R-
DOSP)4, is still unmatched for this type of cyclopropanation
with methyl p-bromophenyldiazoacetate 2 a, whereas other
catalysts are considerably inferior (entry 1–4). A temperature
screen revealed that 0 8C was the optimum condition (en-
tries 5–7). Under these conditions, the cyclopropanation with
methyl phenyldiazoacetate 2 b proceeded in 87 % yield, >30:1
d.r. and 95 % ee.
The next stage was to combine the asymmetric
cyclopropanation with the reductive ring-opening. This reac-
tion was examined with five representative examples of aryl-
diazoacetates, and the results are summarized in Table 3. Rh2(S-
DOSP)4-catalyzed cyclopropanation of aryldiazoacetates 2 a–e
were examined and the cyclopropanes 8 a–e were produced in
high yields (85–93 %) as single diastereomers (>30:1 d.r.) and
moderate to high levels of enantiocontrol (81–95 % ee). The X-
ray structure of 8 b was consistent with cyclopropanation oc-
curring at the Re face of the carbene, which is standard for
Rh2(S-DOSP)4-catalyzed reactions. Reductive ring opening of
the cyclopropanes 8 a–e using Et3SiH and BF3·Et2O
[18] resulting
in concomitant removal of the N-Boc protecting group and the
generation of the desired C3-substituted analogues 9 a–e in
67–92 % yield as single diastereomers (>30:1 dr) and retention
of the asymmetric induction obtained in the cyclopropanation.
The absolute stereochemistry was assigned basing on the crys-
tal structure of trifluoroacetyl-protected 9 a. The retention of
the chirality at the benzylic carbon was proposed to arise from
the formation of a bicyclic intermediate from the ring-opened
enolate, in which the bottom face cis to the bridging hydro-
gens is more accessible.
Two approaches were examined to install the arylacetate
functionality at the C4 position of the piperidine. The first at-
tempt examined the allylic C@H functionalization of N-Boc-di-
Table 2. Optimization studies for cyclopropanation.[a]






1 2 a (Br) R-TCPTAD 23 75 >30:1 3
2 2 a (Br) R-p-BrTPCP 23 73 >30:1 8
3 2 a (Br) S-2-Cl-5-BrTPCP 23 77 >30:1 -69
4 2 a (Br) R-DOSP 23 76 >30:1 -89
5 2 b (H) S-DOSP 23 83 >30:1 -92
6 2 b (H) S-DOSP 0 87 >30:1 95
7 2 b (H) S-DOSP -40 85 >30:1 95
[a] Reaction conditions: a solution of 2 a–e (0.5 mmol) in 12 mL of solvent was added over 2 h to the solution of Rh2L4 (0.5 mol %) and 7 (0.75 mmol) in
2 mL of solvent. [b] Yield of isolated material. [c] Determined from crude 1H NMR. [d] Determined by chiral HPLC analysis of isolated product. A negative
sign indicates that the product is the opposite enantiomer to the one drawn in the Scheme. Boc = tert-butyloxycarbonyl.
Scheme 2. Substrate scope of C2 functionalization. The N-Boc-piperidine
(1 a) functionalization was catalyzed by Rh2(R-TCPTAD)4 to form 5 b–e and N-
Bs-piperidine (1 b) functionalization was catalyzed by Rh2(R-TPPTTL)4 to form
6 b–e. [a] Boc group was removed through trifluoroacetic acid treatment
before analysis. [b] reaction conducted in refluxing CH2Cl2 (39 8C).




hydropyridine 10 as the substrate (Scheme 3). Although the di-
hydropyridine might be expected to be susceptible to cyclo-
propanation rather than C@H functionalization, we had already
established that 1,4-cyclohexadiene strongly favors C@H func-
tionalization.[19] We expected the doubly allylic position in 10
to be similarly activated towards C@H functionalization, and
this proved to be the case. The catalyst screen using the phe-
nyldiazoacetate 2 b revealed that Rh2(R-DOSP)4 is the optimum
catalyst (see the Supporting Information for details). Due to
the instability of the dihydropyridine 10 and the product 11,
the reaction was somewhat challenging and neat conditions
were used for the C@H insertion followed by immediate hydro-
genation of 11. Under these conditions, the C4-substituted
product 12 was obtained in 54 % overall yields and 61 % ee.
A more innovative approach to C4-substituted analogues
would be the direct C@H functionalization on the saturated pi-
peridine derivative. We have already proven that the rhodium-
stabilized donor/acceptor carbenes are sterically demanding
and some of the new catalysts drive the site selectivity away
from the electronically favored sites to the sterically most ac-
cessible sites. Therefore, by appropriate choice of catalyst and
protecting group on nitrogen, we anticipated that it should be
possible to alter the selectivity from C2 to C4 positions. The
optimization study to achieve this goal is shown in Table 4. In
the initial examination of the catalysts in reactions on N-p-bro-
mophenylsulfonyl-piperidine, most of the catalysts gave clean
C2-functionalization selectivity or no reaction (entries 1–3),
while the Rh2(S-2-Cl-5-BrTPCP)4-catalyzed reaction (entry 5) pro-
ceeded with 4.2:1 r.r. favoring the C4 insertion product 13 b in
good yield (67 %) and enantiocontrol (90 % ee). As expected,
the C2 position is less activated with electron-withdrawing
substituent on the arylsulfonyl group and gave slight improve-
ment in the site selectivity (entry 6 vs. , entry 5 and 4). A less
bulky protecting group was expected to have a negative effect
on the steric blocking of the C2 position; however, the smaller
mesyl group caused an increased ratio for the C4 product
(entry 7 vs. entry 4). With limited effect on the site selectivity
with various sulfonyl groups, a more electron-withdrawing pro-
Table 3. Substrate scope of C3-functionalization.[a]





Yield [%] d.r. ee
[%]
1 93 (8 a) 92 67 (9 a) >30:1 93
2 87 (8 b) 95 70 (9 b) >30:1 92
3 86 (8 c) 90 92 (9 c) >30:1 90
4 85 (8 d) 86 77 (9 d) >30:1 87
5 90 (8 e) 81 90 (9 e) >30:1 80
[a] Minimal amount of PhCF3 was added to dissolve the aryldiazoacetate.
Scheme 3. C4-Analog from N-Boc-dihydropyridine.




tecting group, a-oxoarylacetyl group as in 1 f, was utilized for
better selectivity. With this adjustment, the site selectivity be-
tween C4 and C2 improved to >30:1 r.r. and 13 e was formed
in 98 % ee, preferring the S configuration at the benzylic chiral
center according to the crystal structure of 13 b. Switching the
temperature and substrate ratio enhanced the yield (50 % at
23 8C and 1.5:1 1 f :3 a, entry 9 vs. 61 % at 39 8C and 1:1.5
1 f :3 a, entry 11) without influencing the site and enantioselec-
tivity. The efficiency of Rh2(S-2-Cl-5-BrTPCP)4 in C-4 functional-
ization of 1 f was explored using the optimized conditions
(Scheme 4). When the substituents on the aryl ring in the di-
azoacetates were electron-withdrawing (13 f, 13 h) high levels
of enantiocontrol were retained (96–98 % ee) with moderate
yields (50–57 %). When an electron-rich aryl ring in the di-
azoacetate was used, both the yield and the enantioselectivity
decreased (19 % yield, 75 % ee for 13 g).
In summary, this study reveals that by appropriate consider-
ations of the electronic and steric demands of the dirhodium
catalysts, it is possible to functionalize piperidines at C2, C3 or
C4. This leads to the synthesis of a small library of position an-
alogues of methylphenidate.
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Table 4. Optimization studies for C4-functionalization.[a]
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1 1 b R-DOSP 23 <1:30 – –
2 1 b R-TCPTAD 23 <1:30 – –
3 1 b R-p-BrTPCP 23 –[e] – –
4 1 b S-2-Cl-5-BrTPCP 23 4.2:1 76 (13 a) 90
5 1 c S-2-Cl-5-BrTPCP 23 4.0:1 30[f] (13 b) 96
6 1 d S-2-Cl-5-BrTPCP 23 4.7:1 65 (13 c) 96
7 1 e S-2-Cl-5-BrTPCP 23 5.6:1 78 (13 d) 97
8 1 f S-2-Cl-5-BrTPCP 23 >30:1 50 (13 e) 97
9 1 f S-2-Cl-5-BrTPCP 39 >30:1 76 (13 e) 97
10[g] 1 f S-2-Cl-5-BrTPCP 39 >30:1 76 (13 e) 97
[a] Reaction conditions: a solution of 2 b (0.5 mmol) in 4 mL CH2Cl2 was added over 2 h to the solution of Rh2L4 (0.5 mol %) and 1 b–f (0.75 mmol) in 2 mL
CH2Cl2. The reaction was allowed to stir for overnight. [b] Determined by crude
1H-NMR. [c] Yield of isolated material. [d] Determined by chiral HPLC analy-
sis. [e] No C@H functionalization products. [f] 40 % yield of primary C@H insertion on tosyl group. [g] 1.5 equiv of 3 a and 1.0 equiv of 1 f were used.
Scheme 4. Substrate scope of C4 functionalization.
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